Therapeutic developments for multidrug-resistant tuberculosis  

作　　者：Hongfei Duan 

机构地区：[1]Department of Tuberculosis,Beijing Tuberculosis&Thoracic Tumor Research Institute/Beijing Chest Hospital,Capital Medical University,Beijing,China

出　　处：《感染控制(英文)》2024年第4期2-12,共11页

摘　　要：Tuberculosis(TB)remains the leading infectious disease globally,with 1.25 million deaths and 10.8 million new cases in 2023,including 400,000 rifampin-resistant/multidrug-resistant TB(RR/MDR-TB)cases.RR/MDR-TB accounts for 15–20%of TB-related deaths and poses significant economic and treatment challenges due to low cure rates(68%)and high costs.The heterogeneity of Mycobacterium tuberculosis infections complicates therapy,requiring prolonged regimens and multidrug combinations.Advances in treatment include repurposed antibiotics(e.g.,linezolid),re-engineered oxazolidinones(e.g.,sutezolid),and improved bedaquiline analogues addressing resistance and toxicity.Future strategies emphasize shorter,accessible regimens,reliable drug susceptibility testing(DST),and effective management of treatment failures.Targeted next-generation sequencing(tNGS)has improved resistance detection but remains limited for some second-line drugs.Phenotypic DST is still indispensable.Clinicians must address emerging drug resistance and develop salvage regimens while reducing disease transmission through public health measures.These approaches are critical to improving RR/MDR-TB outcomes globally.

关 键 词：TUBERCULOSIS drug resistance bedaquiline drug susceptibility testing next-generation sequencing 

分 类 号：R52[医药卫生—内科学]